Flag of the European Union EU Clinical Trials Register Help

Clinical trials for alpha-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,091 result(s) found for: alpha-. Displaying page 8 of 55.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2007-003718-32 Sponsor Protocol Number: BAY79-4980/12781 Start Date*: 2008-06-27
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week proph...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060613 Hemophilia A (Factor VIII) LLT
    9.1 10018937 Haemophilia A LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) DK (Prematurely Ended) ES (Completed) BE (Completed) AT (Completed) GB (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-002360-28 Sponsor Protocol Number: 104886 Start Date*: 2005-09-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, randomized phase I/II study to demonstrate the non inferiority in term of cellular mediated immune response between GlaxoSmithKline Biologicals influenza candidate vaccines containing vari...
    Medical condition: Immunisation against influenza disease in adults aged 18-40 years and elderly population aged over 65 years (>65 years)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005605-36 Sponsor Protocol Number: SCI-Ta1-NSCLC-CHEMOP2-001 Start Date*: 2016-07-07
    Sponsor Name:SCICLONE PHARMACEUTICALS ITALY S.R.L.
    Full Title: Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
    Medical condition: metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004173-32 Sponsor Protocol Number: 1-10-72-164-15 Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Biochemestry, Aarhus University Hospital
    Full Title: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study.
    Medical condition: Rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005156 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003679-48 Sponsor Protocol Number: CNTO1275AKS3001 Start Date*: 2015-12-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF alpha Naive Subjects With Active Radiograph...
    Medical condition: Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003129-40 Sponsor Protocol Number: FARM125FKN Start Date*: 2017-01-05
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: PHASE 4, MULTICENTER RANDOMISED STUDY, AIMED AT EVALUATING THE MAINTENANCE OF REMISSION AFTER 6, 12, 18 AND 24 MONTHS FROM SUSPENSION OF TNF-ALPHA THERAPIES (ADALIMUMAB, ETANERCEPT, INFLIXIMAB, CER...
    Medical condition: RHEUMATOID ARTHRITIS (RA) PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000120-40 Sponsor Protocol Number: 2006/0606 Start Date*: 2007-06-07
    Sponsor Name:Centre Hospitalier Régional et Universitaire
    Full Title: Etude contrôlée comparative en double aveugle de l'effet d'un traitement par le fénofibrate sur l'expression des génes de l'homéostasie du cholestérol, de l'inflammation et de la prolifération cell...
    Medical condition: Patients présentant des lésions athérosclérosiques carotidiennes asymptomatiques diabétiques ou non diabétiques sous statines .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018531-17 Sponsor Protocol Number: TRED012010 Start Date*: 2010-06-25
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.
    Medical condition: Hypercholesterolaemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001426-24 Sponsor Protocol Number: P02470 Start Date*: 2004-11-23
    Sponsor Name:Prof. Heinz Ludwig, MD, Wilhelminenspital, First Department of Medicine and Medical Oncology
    Full Title: Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy
    Medical condition: First line treatment of multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-001277-25 Sponsor Protocol Number: ST1472-DM-03-004 Start Date*: 2004-09-27
    Sponsor Name:SIGMA-TAU
    Full Title: A Phase III, Multicentre, Double Blinded Study in Patients with Chronic Hepatitis C who are Non-responders to prior PEGinterferon alpha + Ribavirin Therapy Comparing Treatment with Thymosin alpha 1...
    Medical condition: Treatment of Patients with Chronic Hepatitis C who are Non-responders to a course with approved doses of PEGinterferon alpha + Ribavirin
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001653-28 Sponsor Protocol Number: 03/314 Start Date*: Information not available in EudraCT
    Sponsor Name:The Leeds teaching Hospitals NHS trust
    Full Title: A comparison of the effects on prostaglandin synthesis and cytokine production of an olive-oil based lipid emulsion (Clinoloeic) with a soya based emulsion (Intralipid) in newborn infnats receiving...
    Medical condition: Prematurity Parenteral nutrition
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003521-34 Sponsor Protocol Number: CHUBX2015/14 Start Date*: 2015-10-09
    Sponsor Name:CHU de Bordeaux
    Full Title: Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine
    Medical condition: Hypertrophic cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001492-33 Sponsor Protocol Number: CGE_2020_9 Start Date*: 2020-04-10
    Sponsor Name:Hôpital Fondation Adolphe de Rothschild
    Full Title: Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19
    Medical condition: Patients on mechanical ventilation, inpatient resuscitation for ARDS, secondary to COVID-19 infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004756-38 Sponsor Protocol Number: 2018-1201 Start Date*: 2019-02-12
    Sponsor Name:Institut de Cancérologie Lucien Neuwirth
    Full Title: Study of thromboelastography during tranexamic acid treatment in preventing bleeding in patients with haematological malignancies presenting severe thrombocytopenia (TTRAP-bleeding)
    Medical condition: Malignant hemopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003581-20 Sponsor Protocol Number: ALPHA Start Date*: 2023-03-21
    Sponsor Name:Medical University Vienna
    Full Title: Albendazole pharmacokinetics in plasma, intra-cystic fluid, and cystic tissue of human cystic and alveolar echinococcosis
    Medical condition: Albendazole is an orally administered broad-spectrum anthelmintic Drug used in treatment of human alveolar and cystic echinococcosis. To date, data on albendazole and tissue pharmacokinetics are li...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001283-30 Sponsor Protocol Number: SPK-3006-101 Start Date*: 2020-06-16
    Sponsor Name:Spark Therapeutics
    Full Title: Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease
    Medical condition: Pompe Disease (also known as glycogen storage disease type II)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Trial now transitioned) NL (Ongoing) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004300-65 Sponsor Protocol Number: AGO/2016/012 Start Date*: 2017-09-26
    Sponsor Name:Ghent University Hospital
    Full Title: Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFα) blocking Agent by immunoscintigraphy with Technetium-labeled C...
    Medical condition: rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002635-28 Sponsor Protocol Number: OFT-Campos01-12 Start Date*: 2013-04-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY.
    Medical condition: DIABETIC MACULAR EDEMA (DME)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001072-22 Sponsor Protocol Number: T51/2015 Start Date*: 2016-01-26
    Sponsor Name:Turku University Hospital
    Full Title: Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial
    Medical condition: Rhinovirus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039107 Rhinovirus infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000212-34 Sponsor Protocol Number: AG348-C-018 Start Date*: 2021-10-11
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZ...
    Medical condition: Transfusion-Dependent Alpha- or Beta-Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004850 10081904 Transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 06:11:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA